Skip to main content
. Author manuscript; available in PMC: 2023 Apr 1.
Published in final edited form as: Resuscitation. 2022 Feb 8;173:103–111. doi: 10.1016/j.resuscitation.2022.01.033

Table 2:

Comparison of SRCA patients due to opioids/sedatives versus other substance-related cardiac arrests.

Opioid/Sedative
Related
(N=69)
Not
Opioid/Sedative
Related (N=17)
P-Value
Age, years 42 ± 13 40 ± 16 P = 0.52
Sex, female (%) 21/69 (30%) 4/17 (24%) P = 0.77
Non-Shockable rhythm, yes (%) 62/69 (90%) 15/17 (88%) P = 1.0
TTM, yes (%) 57/69 (83%) 15/17 (88%) P = 0.73
Witnessed, yes (%) 24/69 (35%) 8/17 (47%) P = 0.41
Hospital Transfer, yes (%) 17/69 (25%) 8/17 (47%) P = 0.08
Post-ROSC GCS, median [IQR] 3 [3-3] (N=66) 3 [3-3] (N=15) P = 0.77
Pupillary Light Reflex, present (%) 21/63 (33%) 8/13 (62%) P = 0.07
Corneal Reflex, present (%) 8/60 (13%) 0/13 (0%) P = 0.34
Cough reflex, present (%) 11/50 (22%) 4/13 (31%) P = 0.49
Gag reflex, present (%) 17/58 (29%) 3/11 (27%) P = 1.00
Imaging
Time-to-first scan, days median [IQR] 0 [0-1] 0 [0-1] P = 0.45
Multiple scans, yes (%) 51/69 (74%) 13/17 (76%) P = 1.00
Severe Cerebral Edema, yes (%) 31/69 (45%) 5/17 (29%) P = 0.28
Time-to-Severe edema, days median [IQR] 2 [0-3] (N=31) 2 [0-3] (N=5) P = 1.00
Early Severe Cerebral Edema, yes (%) 15/69 (22%) 2/17 (12%) P = 0.50
Cortical injury, yes (%) 51/69 (74%) 11/17 (65%) P = 0.55
Time-to-Cortical Injury, days median [IQR] 2 [0-3] (N=51) 3 [1-4.5] (N=11) P = 0.24
Early Cortical Injury yes (%) 23/69 (33%) 4/17 (24%) P = 0.56
Outcomes
Poor outcome, yes (%) 57/69 (83%) 10/17 (59%) P = 0.0497
In-hospital death, yes (%) 55/69 (80%) 10/17 (59%) P = 0.11
Cause of Death:
Brain Death (%) 11/55 (20%) 1/10 (10%) P = 0.67
Cardiac Death (%) 2/55 (3.6%) 0/10 (0%) P = 1.0
WLST (%) 42/55 (76%) 9/10 (90%) P = 0.68
Time to death, days median [IQR] 5 [3-7] (N=55) 5 [4-6] (N=10) P = 0.79

GCS = Glasgow Coma Scale, NA = Not Applicable, NS = Not selected variable, ROSC = Return of Spontaneous Circulation, TTM = Targeted Temperature Management, WLST = Withdrawal of Life Sustaining Treatment.